Requerimientos para el funcionamiento de la industria de las bebidas de quinua

We have opened a clinical trial with vvdd-hCD40L-tdTomato for dogs with incurable solid tumours. For SFV, more tumour cell lines, especially glioma cells, will be tested for oncolytic capacity of the virus and also the efficacy could be evaluated in tumour biopsies. If the virus proves effective, we intend to open a clinical trial for dogs with glioma as well.

Due to the similarity between canine and human spontaneous tumours (Ranieri et al., 2013, Vail and Thamm, 2011, Vail and MacEwen, 2000), the information yielded from the clinical trials in dogs is anticipated to also benefit human oncology and to reveal key safety and efficacy aspects not evident in rodents.

7 CONCLUSIONS

Based on these studies, the following conclusions can be drawn:

1. Oncolytic vvdd infected and killed canine osteosarcoma (Abrams and D17) and prostatic carcinoma (ACE-1) cell lines, infected canine tumour biopsies and slowed tumour growth in nude mouse prostatic carcinoma (ACE-1) xenograft. Thus, oncolytic vaccine virus expressing hCD40L has anti-tumoural efficacy against tested canine cell lines in vitro and in vivo.

2. Oncolytic vvdd infected and killed feline squamous cell line SCCF1 cells, but the killing efficacy was lost when the cells grew in an intact monolayer. Infectious virions were still produced, but they were morphologically abnormal probable due to their inability to form core units from viral DNA and to form mature virions. Specific features of the cell line may be responsible for the abnormal morphology.

3. Intravenous administration of a high dose of oncolytic Western Reserve vaccinia virus vvdd-tdTomato-hCD40L was safe in healthy dogs despite the potential seizure in one dog. Infectious virus was only found in the blood samples taken immediately after virus infusion and not in saliva, urine or faeces.

4. Attenuated SFV infected and killed tested canine osteosarcoma cell lines (Abrams and D17), and intravenous administration of the virus caused no adverse events in healthy dogs and infectious virus was not found in blood, urine or faeces. Based on our results, attenuated SFV and its derivatives are potential candidates for further studies in canine cancer cell lines, tumour biopsies and finally tumour-bearing dogs.

REFERENCES

Abrahao JS, Trindade Gde S, Ferreira JM, Campos RK, Bonjardim CA, Ferreira PC, Kroon EG. Long-lasting stability of vaccinia virus strains in murine feces: implications for virus circulation and environmental maintenance. Arch Virol 2009, 154: 1551-1553.

Adelfinger M, Gentschev I, Grimm de Guibert J, Weibel S, Langbein-Laugwitz J, Hartl B, Murua Escobar H, Nolte I, Chen NG, Aguilar RJ, Yu YA, Zhang Q, Frentzen A, Szalay AA. Evaluation of a new recombinant oncolytic vaccinia virus strain GLV- 5b451 for feline mammary carcinoma therapy. PLoS One 2014, 9: e104337.

Alcayaga-Miranda F, Cascallo M, Rojas JJ, Pastor J, Alemany R. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Ther 2010, 17: 792-802.

Amantana A, Chen Y, Tyavanagimatt SR, Jones KF, Jordan R, Chinsangaram J, Bolken TC, Leeds JM, Hruby DE. Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection. PLoS One 2013, 8: e61514.

Ansarah-Sobrinho C, Moss B. Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol 2004, 78: 6335-6343.

Appel MJ, Paoletti E. Immune response to vaccinia virus and recombinant virus products in dogs. Am J Vet Res 1988, 49: 1932-1934.

Barrett AD, Dimmock NJ. Modulation of Semliki Forest virus-induced infection of mice by defective-interfering virus. J Infect Dis 1984, 150: 98-104.

Benbough JE. The effect of relative humidity on the survival of airborne Semliki Forest virus. J Gen Virol 1969, 4: 473-477.

Bennett M, Gaskell RM, Gaskell CJ, Baxby D, Kelly DF. Studies on poxvirus infection in cats. Arch Virol 1989, 104: 19-33.

Bereta M, Bereta J, Park J, Medina F, Kwak H, Kaufman HL. Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles. Cancer Gene Ther 2004, 11: 808-818.

Berglund P, Fleeton MN, Smerdou C, Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999, 17: 497-507.

Bergvist GT, Yool DA. Epidermal growth factor receptor as a therapeutic target in veterinary oncology. Veterinary and comparative oncology 2010, 9: 81-94.

Bradish CJ, Allner K. The early responses of mice to respiratory or intraperitoneal infection by defined virulent and avirulent strains of Semliki Forest virus. J Gen Virol 1972, 15: 205-218.

Bradish CJ, Allner K, Maber HB. The virulence of original and derived strains of Semliki Forest virus for mice, guinea-pigs and rabbits. J Gen Virol 1971, 12: 141-160. Bradish CJ, Allner K, Maber HB. Infection, interaction and the expression of virulence by defined strains of Semliki Forest virus. J Gen Virol 1972, 16: 359-372.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011, 477: 99-102.

Brochier B, Aubert MF, Pastoret PP, Masson E, Schon J, Lombard M, Chappuis G, Languet B, Desmettre P. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev Sci Tech 1996, 15: 947- 970.

Bull LB, Dickinson CG. The specificity of the virus of rabbit myxomatosis. Journal of the Council of Scientific and Industrial Research 1937, 10: 291-294.

Buller RM, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988, 62: 866-874.

Buonagurio DA, Coleman JW, Patibandla SA, Prabhakar BS, Tatem JM. Direct detection of Sabin poliovirus vaccine strains in stool specimens of first-dose vaccinees by a sensitive reverse transcription-PCR method. J Clin Microbiol 1999, 37: 283-289. Center for Disease Control and Prevention. Smallpox vaccination. 2008. http://www.bt.cdc.gov/agent/smallpox/vaccination. Accessed 15 Nov 2013.

Centers for Disease Control and Prevention (CDC). Human vaccinia infection after contact with a raccoon rabies vaccine bait - Pennsylvania, 2009. MMWR Morb Mortal Wkly Rep 2009, 58: 1204-1207.

Cerullo V, Diaconu I, Romano V, Hirvinen M, Ugolini M, Escutenaire S, Holm SL, Kipar A, Kanerva A, Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol Ther 2012a, 20: 2076-2086.

Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res 2012b, 115: 265-318.

Chinsangaram J, Honeychurch KM, Tyavanagimatt SR, Leeds JM, Bolken TC, Jones KF, Jordan R, Marbury T, Ruckle J, Mee-Lee D, Ross E, Lichtenstein I, Pickens M, Corrado M, Clarke JM, Frimm AM, Hruby DE. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers. Antimicrob Agents Chemother 2012, 56: 4900-4905.

Condit RC, Moussatche N, Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv Virus Res 2006, 66: 31-124.

Cono J, Casey CG, Bell DM, Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003, 52: 1-28.

Diaconu I, Cerullo V, Hirvinen ML, Escutenaire S, Ugolini M, Pesonen SK, Bramante S, Parviainen S, Kanerva A, Loskog AS, Eliopoulos AG, Pesonen S, Hemminki A. Immune response is an important aspect of the antitumor effect produced by a CD40L- encoding oncolytic adenovirus. Cancer Res 2012, 72: 2327-2338.

Earl PL, Moss B, Wyatt LS, Carroll MW. Preparation of cell cultures and vaccinia virus stock. In: Current protocols in molecular biology, vol. 2. Greene Publishing Associates and Wiley International, New York, NY, USA 1998: 16.17.1-16.17.19. Elsedawy NB, Russell SJ. Oncolytic vaccines. Expert Rev Vaccines 2013, 12: 1155- 1172.

Essbauer S, Meyer H, Porsch-Ozcurumez M, Pfeffer M. Long-lasting stability of vaccinia virus (orthopoxvirus) in food and environmental samples. Zoonoses Public Health 2007, 54: 118-124.

Essbauer S, Pfeffer M, Meyer H. Zoonotic poxviruses. Vet Microbiol 2010, 140: 229- 236.

Fazakerley JK. Pathogenesis of Semliki Forest virus encephalitis. J Neurovirol 2002, 8 Suppl 2: 66-74.

Fazakerley JK, Pathak S, Scallan M, Amor S, Dyson H. Replication of the A7(74) strain of Semliki Forest virus is restricted in neurons. Virology 1993, 195: 627-637. Fenner F, World Health Organization. Smallpox and its eradication. World Health Organization, Geneva 1988.

Finnish National Institute for Health and Welfare. Isorokko. 2013. http://www.thl.fi/en/web/infektiotaudit/taudit-ja-mikrobit/virustaudit/isorokko. Accessed 31 Jan 2015.

Fleming P. Age-dependent and strain-related differences of virulence of Semliki Forest virus in mice. J Gen Virol 1977, 37: 93-105.

Fragkoudis R, Ballany CM, Boyd A, Fazakerley JK. In Semliki Forest virus encephalitis, antibody rapidly clears infectious virus and is required to eliminate viral material from the brain, but is not required to generate lesions of demyelination. J Gen Virol 2008, 89: 2565-2568.

Fragkoudis R, Breakwell L, McKimmie C, Boyd A, Barry G, Kohl A, Merits A, Fazakerley JK. The type I interferon system protects mice from Semliki Forest virus by preventing widespread virus dissemination in extraneural tissues, but does not mediate the restricted replication of avirulent virus in central nervous system neurons. J Gen Virol 2007, 88: 3373-3384.

Galic MA, Riazi K, Pittman QJ. Cytokines and brain excitability. Front Neuroendocrinol 2012, 33: 116-125.

Genelux Inc. 2013. Genelux Corporation. http://www.genelux.com. Accessed 15 Nov 2014.

Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, Weibel S, Chen NG, Yu YA, Zhang Q, Heisig M, Thamm D, Stritzker J, Macneill A, Szalay AA. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One 2012, 7: e37239.

Gentschev I, Ehrig K, Donat U, Hess M, Rudolph S, Chen N, Yu YA, Zhang Q, Bullerdiek J, Nolte I, Stritzker J, Szalay AA. Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. J Oncol 2010, 2010: 736907.

Gentschev I, Patil SS, Adelfinger M, Weibel S, Geissinger U, Frentzen A, Chen NG, Yu YA, Zhang Q, Ogilvie G, Szalay AA. Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy. Bioengineered 2013, 4: 84-89.

Gentschev I, Patil SS, Petrov I, Cappello J, Adelfinger M, Szalay AA. Oncolytic virotherapy of canine and feline cancer. Viruses 2014, 6: 2122-2137.

Gentschev I, Stritzker J, Hofmann E, Weibel S, Yu YA, Chen N, Zhang Q, Bullerdiek J, Nolte I, Szalay AA. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 2009, 16: 320-328.

Greiner S, Humrich JY, Thuman P, Sauter B, Schuler G, Jenne L. The highly attenuated vaccinia virus strain modified virus Ankara induces apoptosis in melanoma cells and allows bystander dendritic cells to generate a potent anti-tumoral immunity. Clin Exp Immunol 2006, 146: 344-353.

Griffin DE. Alphaviruses. In: Fields,BN, Knipe,DM, Howley,PM (eds.) Fields' virology. 5th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia 2007: 1023-1065.

Guo ZS, Liu Z, Bartlett DL. Oncolytic Immunotherapy: Dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014, 4: 74.

Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y, Yin X, Yang S, Zeh HJ, Moss B, Lotze MT, Bartlett DL. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005, 65: 9991-9998.

Guse K, Sloniecka M, Diaconu I, Ottolino-Perry K, Tang N, Ng C, Le Boeuf F, Bell JC, McCart JA, Ristimäki A, Pesonen S, Cerullo V, Hemminki A. Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. J Virol 2010, 84: 856-866.

Hardy PA, Mazzini MJ, Schweitzer C, Lundström K, Glode LM. Recombinant Semliki Forest virus infects and kills human prostate cancer cell lines and prostatic duct epithelial cells ex vivo. Int J Mol Med 2000, 5: 241-245.

Hawranek T, Tritscher M, Muss WH, Jecel J, Nowotny N, Kolodziejek J, Emberger M, Schaeppi H, Hintner H. Feline orthopoxvirus infection transmitted from cat to human. J Am Acad Dermatol 2003, 49: 513-518.

Heikkilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, Bell JC, Hinkkanen AE. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010, 5: e8603.

Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther 2003, 7: 163-173.

Hemminki O, Bauerschmitz G, Hemmi S, Lavilla-Alonso S, Diaconu I, Guse K, Koski A, Desmond RA, Lappalainen M, Kanerva A, Cerullo V, Pesonen S, Hemminki A. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 2011, 18: 288-296. Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013, 19: 329-336. Hollinshead M, Vanderplasschen A, Smith GL, Vaux DJ. Vaccinia virus intracellular mature virions contain only one lipid membrane. J Virol 1999, 73: 1503-1517. Hu MH, Huang GS, Wu CT, Lin JJ, Hsia SH, Wang HS, Lin KL, the CHEESE Study Group. Analysis of plasma multiplex cytokines for children with febrile seizures and severe acute encephalitis. J Child Neurol 2014, 29: 182-6.

Hwang CC, Umeki S, Igase M, Coffey M, Noguchi S, Okuda M, Mizuno T. The effects of oncolytic reovirus in canine lymphoma cell lines. Vet Comp Oncol 2014, DOI: 10.1111/vco.12124

Hwang CC, Umeki S, Kubo M, Hayashi T, Shimoda H, Mochizuki M, Maeda K, Baba K, Hiraoka H, Coffey M, Okuda M, Mizuno T. Oncolytic reovirus in canine mast cell tumor. PLoS One 2013, 8: e73555.

Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, Daneshmand M, De Silva N, Parato K, Diallo JS, Lee YS, Liu TC, Bell JC, Kirn DH. A Mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther 19:1913-1922. Mol Ther 2011, 19: 1013-1922.

Igase M, Hwang CC, Coffey M, Okuda M, Noguchi S, Mizuno T. The oncolytic effects of reovirus in canine solid tumor cell lines. J Vet Med Sci 2015, Jan 16. [Epub ahead of print].

Jagelman S, Suckling AJ, Webb HE, Bowen FT. The pathogenesis of avirulent Semliki Forest virus infections in athymic nude mice. J Gen Virol 1978, 41: 599-607. Jaime JCJ, Young AM, Mateo J, Yap TA, Denholm KA, Shah KJ, Tunariu N, Sassi S, Karapanegiotou L, Mansfiedl D, Molife LR, Harrington KJ, De Bono JS. Phase 1 clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. J Clin Oncol 2012, 30: (suppl; abstr 2530). Jourdier TM, Moste C, Bonnet MC, Delisle F, Tafani JP, Devauchelle P, Tartaglia J, Moingeon P. Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2). Gene Ther 2003, 10: 2126- 2132.

Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P, Landron S, Bigot L, Nemati F, Dartigues P, Weiswald LB, Lantuas D, Morgand L, Pham E, Gonin P, Dangles-Marie V, Job B, Dessen P, Bruno A, Pierre A, De The H, Soliman H, Nunes M, Lardier G, Calvet L, Demers B, Prevost G, Vrignaud P, Roman-Roman S, Duchamp O, Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 2012, 18: 5314-5328.

Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U. Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 2006, 108: 3253-3261.

Kaneko K, Fukuda H, Chuang VT, Yamasaki K, Kawahara K, Nakayama H, Suenaga A, Maruyama T, Otagiri M. Subdomain IIIA of dog albumin contains a binding site similar to site II of human albumin. Drug Metab Dispos 2008, 36: 81-86.

Kelly WR, Blakemore WF, Jagelman S, Webb HE. Demyelination induced in mice by avirulent Semliki Forest virus. II. An ultrastructural study of focal demyelination in the brain. Neuropathol Appl Neurobiol 1982, 8: 43-53.

Ketola A, Hinkkanen A, Yongabi F, Furu P, Määttä AM, Liimatainen T, Pirinen R, Björn M, Hakkarainen T, Mäkinen K, Wahlfors J, Pellinen R. Oncolytic Semliki Forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res 2008, 68: 8342-8350.

Kim JH, Oh JY, Park BH, Lee DE, Kim JS, Park HE, Roh MS, Je JE, Yoon JH, Thorne SH, Kirn D, Hwang TH. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006, 14: 361-370.

Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi- mechanistic therapeutic class for cancer. Nat Rev Cancer 2009, 9: 64-71.

Kotwal GJ, Abrahams M. Growing Poxviruses and Determining Virus Titer. In: Isaacs,SN (ed.) Vaccinia Virus and Poxvirology. 1st ed. Human Press, New Jersey, US 2004: 101-112.

Kraaijeveld CA, Schilham M, Jansen J, Benaissa-Trouw B, Harmsen M, van Houte AJ, Snippe H. The effect of liposomal charge on the neutralizing antibody response against inactivated encephalomyocarditis and Semliki Forest viruses. Clin Exp Immunol 1984, 56: 509-514.

Krauss H, Weber A, Appel M, Enders B, Isenberg HD, Schiefer HG, Slenczka HG, Graevenitz AA, Zahner H. Viral Zoonoses. In: Krauss,H (ed.) Zoonoses: infectious diseases transmissible from animals to humans, 3rd ed. 3 ed. ASM Press, Washington, D.C. 2003: 7-8, 14-15.

Kroon EG, Mota BE, Abrahao JS, da Fonseca FG, de Souza Trindade G. Zoonotic Brazilian vaccinia virus: from field to therapy. Antiviral Res 2011, 92: 150-163. Laborda E, Puig-Saus C, Rodriguez-Garcia A, Moreno R, Cascallo M, Pastor J, Alemany R. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Mol Ther 2014, 22: 986- 998.

Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther 2006, 13: 389-399.

LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Hum Gene Ther Clin Dev 2013, 24: 174-181.

Lederman E, Miramontes R, Openshaw J, Olson VA, Karem KL, Marcinak J, Panares R, Staggs W, Allen D, Weber SG, Vora S, Gerber SI, Hughes CM, Regnery R, Collins L, Diaz PS, Reynolds MG, Damon I. Eczema vaccinatum resulting from the transmission of vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment. Vaccine 2009, 27: 375-377.

Lederman ER, Davidson W, Groff HL, Smith SK, Warkentien T, Li Y, Wilkins KA, Karem KL, Akondy RS, Ahmed R, Frace M, Shieh WJ, Zaki S, Hruby DE, Painter WP, Bergman KL, Cohen JI, Damon IK. Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001. J Infect Dis 2012, 206: 1372-1385.